Biolase entered the deal with an unnamed institutional investor, according to a June 28 news release.
Under the terms of the agreement, Biolase will sell 1,405,405 shares of common stock or pre-funded warrants in a registered direct offering. The company will also issue warrants to purchase common stock in a private placement.
The deal is expected to close on or about June 30.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
